Cyclacel Pharmaceuticals, Inc. Share Price
Equities
CYCC
US23254L8019
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.51 USD | -5.62% | -15.17% | -43.45% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.99M 159M |
---|---|---|---|---|---|
Net income 2024 * | -23M -1.84B | Net income 2025 * | -26M -2.08B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.11
x | P/E ratio 2025 * |
-0.06
x | Employees | 12 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.05% |
Latest transcript on Cyclacel Pharmaceuticals, Inc.
1 day | -5.63% | ||
1 week | -15.17% | ||
Current month | -28.43% | ||
1 month | -21.35% | ||
3 months | -28.77% | ||
6 months | -81.72% | ||
Current year | -43.45% |
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 31/07/97 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 31/12/01 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 16/12/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 28/02/06 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 16/12/20 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 31/07/97 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.51 | -5.63% | 181,642 |
25/04/24 | 1.6 | -30.43% | 3,489,580 |
24/04/24 | 2.3 | +28.49% | 551,102 |
23/04/24 | 1.79 | +2.29% | 28,374 |
22/04/24 | 1.75 | -1.69% | 25,527 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.45% | 1.99M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CYCC Stock